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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
curcuminoids are effective in reducing pain in adults with knee osteoarthritis.  
 
STUDY DESIGN: This is a systematic review which evaluates three randomized controlled 
trials (RCT’s) published in peer reviewed journals between 2016-2018. 
 
DATA SOURCES: The data sources used for this review were found using PubMed and 
Cochrane Library. Data was chosen based on relevance to the clinical question and if patient-
oriented evidence that matters (POEMS) were included.   
 
OUTCOMES MEASURED: All three studies measured curcuminoids and its effects on pain 
reduction in adults with knee osteoarthritis using the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC), a self-administered questionnaire consisting of 24 items divided 
into 3 subscales: Pain (5), Stiffness (2), Physical Function (17).  
 
RESULTS: All three studies contained continuous data, therefore, p-values were reported for 
each of the studies. A p-value of ≤0.05 was reported by all three RCTs, thus concluding the data 
to be statistically significant. Each of the studies found with statistical significance that 
curcuminoids reduced pain in the adults with knee osteoarthritis reported by the participants of 
the trials. A study by Haroyan et al. (BMC complementary and alternative medicine. 
2018;18(1):7. https://www.ncbi.nlm.nih.gov/pubmed/29316908. doi: 10.1186/s12906-017-2062-
z.) concluded that curcuminoids in combination with boswellic acid may be more effective than 
curcuminoids alone when evaluating efficacy of pain reduction in adults with knee osteoarthritis.  
 
CONCLUSIONS: After analysis of the three randomized controlled trials, evidence conducted 
in this review is conclusive that the use of curcuminoids can effectively reduce pain in adults 
with knee osteoarthritis.  
 
KEYWORDS: Turmeric, curcumin, curcuma, curcuminoids, osteoarthritis 
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INTRODUCTION 
Osteoarthritis (OA) is the most common form of arthritis and is often referred to as 
degenerative joint disease or “wear and tear” arthritis. OA occurs when the articular cartilage 
within a joint begins to break down, ultimately leading to underlying bony changes of the joint. 
Among the joints of the body, the knee is the most commonly involved joint.1 The etiology and 
risk factors for knee OA are multifactorial and individuals at risk for developing knee OA 
include women over the age of 50, those with previous injury or overuse to the joint and those 
who are considered obese or genetically predisposed.2,3 Knee joint changes usually worsen over 
time and can eventually lead to pain, stiffness, swelling and decreased range of motion of the 
damaged joint. In severe cases, knee osteoarthritis can cause reduced function and the inability to 
complete daily tasks or work— making it the leading cause of chronic disability in the United 
States.3,4 
Osteoarthritis is significant for its high prevalence among the general population, 
affecting 40 million adults in the United States, with nearly ninety percent of the population 
having radiographic features of OA in weight-bearing joints by age 40.4 The economic costs of 
OA remain high especially regarding treatment. In 2013, osteoarthritis was the second most 
costly health condition to be treated at U.S. hospitals— accounting for 16.5 billion dollars of the 
combined costs for all hospitalizations.3 Osteoarthritis also accounted for approximately 20.78 
million ambulatory care visits and 2.95 million inpatient hospitalizations in 2013.5 As the U.S. 
population continues to age, the prevalence of diagnosed osteoarthritis is expected to increase. 
According to the CDC, it is estimated that 78.4 million adults aged 18 years and older will have 
doctor-diagnosed arthritis by the year 2040.3 This increase in prevalence will create opportunity 
for more mid-level providers such as physician assistants and nurse practitioners to manage 
patients with osteoarthritis and contribute to overall patient satisfaction and outcomes.    
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It is known that knee osteoarthritis occurs when all structures of the joint have undergone 
pathologic change and is primarily a result of the degeneration of cartilage and hypertrophy of 
bone at the articular margins.4 Pain is the most common symptom experienced in knee OA as a 
result of these degenerative changes and ranges in severity from mild to immobilizing.2 Pain 
experienced with knee OA is exacerbated with weight-bearing activities such as walking, 
standing or climbing stairs, and is typically relieved upon rest.2  
Once an individual is diagnosed with osteoarthritis, the focus of treatment is to control 
symptoms by reducing pain and improving joint function. Conservative approaches to pain 
reduction in individuals suffering from knee OA include exercise, weight loss and supportive 
measures such as braces.4 However, more commonly, individuals with knee OA will turn to 
pharmacological treatments to address their pain. Current knee OA treatments rely on oral 
analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) such as acetaminophen, 
ibuprofen, naproxen and celecoxib as well as topical therapies like diclofenac gel.4,6 In severe 
cases where oral or topical therapies fail, intra-articular corticosteroid or hyaluronic acid 
injections are considered.4 Surgical options such as arthrocentesis debridement and partial or 
total knee replacements are reserved for individuals who have failed the previously mentioned 
treatment modalities.4  
While these conventional treatment options seem to be effective, most current OA 
treatments are associated with a wide range of adverse effects and drug interactions.6 
Particularly, NSAIDs are one of the most commonly used medications for the treatment of knee 
OA. However, prolonged use of NSAIDs may be intolerable to some patients due to its side 
effects on the gastrointestinal system, which include dyspepsia, ulceration, upper gastrointestinal 
bleeding and perforation of the stomach or duodenum.2 Additionally, long-term use of NSAIDs 
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has also shown to cause damage to the kidneys. Therefore, it is proposed that curcuminoids, a 
family of natural chemical compounds found in the plant Curcuma longa, commonly known as 
Turmeric, may provide an alternative medicinal option for pain relief in patients with knee 
osteoarthritis with fewer side effects. Through research, curcuminoids have shown to possess 
anti-inflammatory properties by inhibiting enzymes involved in inflammation such as 
cyclooxygenase (COX-2), and by inhibiting the production of inflammatory cytokines such as 
interferon, interleukins and tumor necrosis factor.2  
OBJECTIVE 
The objective of this selective evidence-based medicine (EBM) review is to determine 
whether or not curcuminoids are effective in reducing pain in adults with knee osteoarthritis. 
METHODS 
 The studies selected for analysis included three randomized, double-blind, clinical 
controlled trials evaluating both male and female patients over the age of 40 years old diagnosed 
with primary knee osteoarthritis (see Table 1). Each study included a randomized group that 
received some form of oral curcuminoid therapy compared to a control group which received a 
placebo or ibuprofen. Outcomes measured in each study include knee pain, joint stiffness and 
physical function. The focus of this systematic review will be on knee pain.  
Minor variations in each of the studies did exist, including age groups, curcuminoid 
product and dosage, adjunctive treatment, group size and duration of treatment (see Table 1). 
The study conducted by Haroyan et al. compared the change in baseline of patients between the 
ages of 40 to 77 years old receiving CuraMed® 500 mg capsules (333 mg curcuminoids) and 
patients receiving Curamin® 500 mg capsules (350 mg curcuminoids and 150 mg boswellic acid) 
and a control group receiving a placebo taken three times daily for 12 weeks.6 The study 
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conducted by Srivastava et al. compared the change in baseline of patients between the ages of 
40 to 80 years old receiving 500 mg of curcuma longa extract and a control group receiving 500 
mg of placebo capsules taken twice daily along with the standard treatment of Diclofenac 50 mg 
twice daily for 4 months.1 The study conducted by Ross compared the change in baseline of 
patients older than 50 years old receiving 1500 mg daily of curcumin extract and a group 
receiving 1200 mg daily of ibuprofen with the exception of tramadol for severe pain as needed 
for 4 weeks.2 
All articles selected for this systematic review were found using the search engine on 
PubMed and Cochrane Library databases with the use of key words “turmeric”, “curcumin”, 
“curcuma”, “curcuminoids” and “osteoarthritis”. The studies were further filtered by articles 
published in the English language and in peer reviewed journals. Articles were then selected 
based on their relevance to the clinical question and if patient-oriented evidence that matters 
(POEMs) were the outcomes measured. Inclusion criteria included studies that were RCTs 
published during or after 2016 due to a systematic review being completed prior to 2016. 
Exclusion criteria included studies published before 2016, systematic reviews published after 
selected RCTs and rheumatoid arthritis. All three studies selected contain non-dichotomous data 
with data reported in p-values, confidence intervals, and mean change from baseline. See Table 1 
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OUTCOMES MEASURED  
 The outcomes measured in all three RCTs were patient-oriented evidence that matters 
(POEMs) with these outcomes focusing on knee pain, joint stiffness and physical function in 
patients with primary knee osteoarthritis. The Haroyan et al. study used Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC), a self-administered questionnaire asking 
patients to measure their symptoms of knee pain, joint stiffness and physical function at baseline 
and at weeks 4 and 12 of treatment.6 This study also used OA physical performance measures 
such as 30-second stand test, 40-meter fast-paced walk test, the “timed up and go” test, and the 
stair climb test.6 The Srivastava et al. study used WOMAC scores and a visual analog scale 
(VAS) to evaluate change at baseline, 2 months and 4 months.1 The Ross study assessed 
outcomes using a modified Thai version of WOMAC scores and a 6-minute walk distance at 
weeks 0, 2 and 4.2 The focus of this systematic review will be on knee pain and WOMAC pain 
measurement scores due to consistency of this measurement throughout all three RCTs. A higher 
WOMAC score is indicative of greater pain and poorer function.1 
RESULTS 
 This systematic review includes three randomized controlled trials evaluating the 
efficacy of curcuminoids on knee pain in patients with knee osteoarthritis. All three studies use 
some form of curcuminoids as experimental therapy while the control group of the studies vary 
between the use of placebos and ibuprofen. The inclusion and exclusion criteria also vary 
between each of the studies (see Table 1). All three selected studies did not have dichotomous 
data; therefore, results were reported as continuous data. Statistics among the selected studies 
were reported through mean changes from baseline, p-values and confidence intervals (CI).   
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The 2018 study by Haroyan et al. is a three-armed randomized, double-blind, controlled 
trial that evaluates the efficacy of CuraMed versus Curamin versus that of a placebo group 
through WOMAC scores at baseline and at 4 and 12 weeks.6 Patients included in this trial were 
of the ages 40 to 80 years old and selected based on their diagnosis of degenerative hypertrophic 
knee osteoarthritis— ultimately, 201 patients were enrolled for evaluation with a total of 179 
patients completing treatment.6 All patients were randomly allocated to groups by the principal 
investigator with a randomization code, which was not revealed until the end of the study.6 See 
Table 1 for details of interventions and exclusion criteria of this trial. A compliance rate is not 
reported within the trial, however, the author noted that compliance was measured individually 
through special forms given to the participants to record their daily consumption of capsules.6 
These forms were then evaluated periodically throughout the trial by the investigators to ensure 
compliance. This trial found that the baseline WOMAC pain score of 5.91 ± 2.77 significantly 
decreased in the CuraMed (curcuminoids) group after twelve weeks of treatment with a 12-week 
WOMAC pain score of 3.84 ± 2.88.6 A statistically significant difference was found within the 
CuraMed group with a p-value less than 0.001 and a confidence interval of 95 percent, however, 
when comparing CuraMed to the placebo, the calculated p-value was greater than 0.05.6 The 
Curamin group (curcuminoids and boswellic acid combination) when compared to the placebo 
group had a p-value < 0.05.6 There was no intergroup comparison between CuraMed and 
Curamin. Ultimately, this study concluded that statistically significant pain relief was observed 
in all study groups, including the placebo, but that these plant extracts when used in combination 
prove to be more effective.6 Refer to Table 2 for WOMAC pain scores at different intervals for 
each of the respective groups. Regarding safety profile, all the medications were well tolerated.6 
Similar and minor adverse effects were noted in 13 of the 201 patients including 7 in the 
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CuraMed group, 2 in the Curamin group and 4 in the placebo group with nausea being the only 
side effect noted in the curcuminoid-containing supplements.6 Other common side effects 
included gastrointestinal symptoms and weight gain.6  
 
Table 2— CuraMed vs. Curamin vs. Placebo WOMAC Pain Index subscale (Haroyan et al. 2018)6 
 Baseline Week 4 Week 12 P-value 
within 
group 
Intergroup comparison, mean change from 
baseline to week 12, p-values  
Placebo vs CuraMed Placebo vs Curamin 
CuraMed  
(n=66) 





< 0.05 Curamin 
(n=67) 
6.39 ± 3.47 5.02 ± 3.46 4.49 ± 3.86 P<0.0001 
Placebo 
(n=68) 
5.85 ± 3.25 4.92 ± 3.09 5.22 ± 3.58 P<0.003 
  
The 2016 study by Srivastava et al. is a two-armed randomized, double-blind, controlled 
trial which compares the efficacy of curcuminoid extract to a placebo group in 160 patients using 
WOMAC scores at baseline, 2 months and 4 months.1 VAS scores were also assessed during this 
trial but will not be included in this review due to the focus of this analysis being on knee pain 
and WOMAC scores. Patients included in this trial were of ages 40 to 80 years old and 
diagnosed with primary knee osteoarthritis. Of the 160 patients, 27 patients were lost to follow 
up during the trial.1 All subjects were assigned to their respective groups by computerized 
randomization.1 See Table 1 for details regarding exclusion criteria and interventions. Overall, 
this trial found that treatment with curcuminoids extract was associated with a significantly 
greater reduction in WOMAC pain scores (p<0.05) compared to the placebo group.1 The mean 
difference baseline WOMAC pain score in the curcuminoid group started at 15.10 ± 0.31 and 
decreased to a pain score of 9.48 ± 0.17 by the end of the study at month four.1 Refer to Table 3 
for WOMAC pain scores and p-values at different intervals for each of the respective groups. 
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More adverse effects were noted in the placebo group (n=4) compared to the curcuminoid group 
(n=2) with nausea, vomiting and dyspepsia being the most common side effects in both groups.1  
Table 3— Effect of Treatment on WOMAC Pain Scores (Srivastava et al. 2016)1 
 Baseline 2-Month 4-Month 
Curcuma longa extract (n=78) 15.10 ± 0.31 11.19 ± 0.26 9.48 ± 0.17 
Placebo (n=82) 15.29 ± 0.26 12.05 ± 0.21 10.16 ± 0.16 
P-values 0.64 0.01 0.06 
 The 2016 study by Ross is a randomized, double-blind, controlled trial which assessed 
the efficacy of curcuminoid extract in pain reduction compared with ibuprofen in 367 patients 
over the age of 50 years old diagnosed with primary knee osteoarthritis using WOMAC scores 
and 6-minute walk test.2 For the purpose of this review, only WOMAC pain scoring will be 
discussed for relevancy to topic. All patients were randomly allocated to receive either 1500 mg 
of curcuminoids or 1200 mg of ibuprofen daily for 4 weeks.2 Of the 367 patients, 36 were lost to 
follow up during the trial.2 See Table 1 for exclusion criteria and interventions. This study 
concluded that the mean of all WOMAC scores at baseline, week 2, and week 4 showed a 
significant improvement in pain in both the curcuminoid and ibuprofen group from baseline 
(p<0.05).2 A confidence interval of 95 percent and WOMAC pain score with a p-value of 0.018 
was noted in the curcuminoid group.2 The number of patients experiencing adverse effects was 
similar among both groups, however, gastrointestinal side effects were much higher in the 
ibuprofen group compared to the curcuminoid group (p=0.046).2 Compliance with treatment was 
not measured for this trial.  
DISCUSSION 
 All three studies evaluated in this systematic review suggest that short-term use of 
curcuminoids may be beneficial in the reduction of pain in patients suffering from knee 
osteoarthritis, however, certain limitations in the studies should be taken into consideration. All 
three studies used similar populations by utilizing adults diagnosed with primary knee 
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osteoarthritis over the ages of 40 years old of both sexes. Sample size is also an important factor 
in determining the validity of a study. All three trials seemed to have larger population sizes 
including a total of 167, 201 and 367 patients, however, the duration of the trials varied between 
all three with final treatments occurring at 1 month, 3 months and 4 months. This variation in 
time between the studies may be considered a limitation.  
 The Haroyan et al. study calculated that a sample size of 180 participants was enough to 
be statistically significant study, therefore, a total of 201 patients were enrolled to compensate 
for non-compliance.6 Ultimately, 22 patients (10.5%) were lost to follow up due to various 
reasons, with a total of 179 patients completing the treatment.6 Even though sample size does not 
limit this study, the means of intervention may be considered a constraint on the study. Due to 
the hydrophobic nature of curcuminoids, turmeric volatile oil and other sesquiterpenes were 
added to curcuminoids to make an extract known as BCM-95 to increase bioavailability in 
CuraMed and Curamin.6 These additives may have a direct effect on the outcome evaluated in 
the study.  
 Likewise, two of the studies used adjunctive treatment throughout the trials which may 
have skewed the outcomes. The Srivastava et al. study allowed patients to use diclofenac 50 mg 
twice daily, a standard treatment for osteoarthritis, along with the experimental therapy of 
curcuminoids.1 The Ross study allowed patients to use Tramadol as needed for severe pain with 
curcuminoid therapy without mentioning the frequency and dosage of Tramadol taken by the 
participants.2 
Curcuminoids, sold commonly under the turmeric, are widely available at nearly any 
grocery, drug or vitamin store in the United States. While several forms of curcuminoid products 
exist, no form of curcuminoids has been approved by the Food and Drug Administration (FDA) 
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for the treatment of a specific medical condition. According to the National Institutes of Health 
(NIH), curcuminoids are generally considered safe when taken in oral or topical form but high-
doses or long-term use may cause gastrointestinal symptoms.7 The three RCTs used for this 
analysis all stated that a small number of participants experienced some form of gastrointestinal 
symptoms which supports this statement by the NIH. While no absolute contraindications or 
black box warnings exist for curcuminoids, it is suggested those allergic to curcuminoids and 
those with gallstones, bile duct obstruction, or diabetes caution use due to the possibility for 
curcuminoids decreasing blood sugar.8 Even though curcuminoids are not approved by the FDA, 
it is of interest to note whether curcuminoid-containing products would be covered by insurance 
as a form of pharmacological therapy upon approval.  
CONCLUSION 
 Based on these three studies, curcuminoids are an effective and relatively safe alternative 
to conventional treatment to reduce knee pain in adults with osteoarthritis. All three studies 
showed a decrease in pain from baseline which proves its efficacy in therapy. One study 
concluded that curcuminoids when used in combination with another herbal supplement, 
boswellic acid, shows more effectiveness than when used alone. This is an interesting finding 
and further evaluation through future studies is recommended.  Other future studies could 
investigate curcuminoids and its use in the prevention of osteoarthritis rather than treatment. 
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